Q-omics provides the consensus-scored UBTFL11 profile across patient tissues and cancer cell-line models. UBTFL11 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, UBTFL11 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, UBTFL11 RNA expression shows 6,354 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, LUSC, and STAD as cancer lineages where UBTFL11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBTFL11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBTFL11 survival associations across molecular data types. UBTFL11 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBTFL11 RNA expression–survival associations across cancer types. High UBTFL11 expression shows unfavorable associations in KICH, ACC, READ and KIRC, but favorable associations in BLCA and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for UBTFL11 RNA expression.
This table summarizes UBTFL11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for UBTFL11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBTFL11 shows lower tumor expression in LUSC and THCA and higher tumor expression in UCEC. The LUSC box plot shows higher UBTFL11 RNA expression in normal versus tumor tissue (log2 FC = −0.013, t-test p = .013).
This table shows molecular features associated with UBTFL11 in patient tissues and cancer cell lines. In patient samples, UBTFL11 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
